 |
|
Comparison of Ketanserin and Metoprolol in the Treatment of Essential Hypertension
Sheldon G. Sheps, MD;
Alexander Schirger, MD;
Prince K. Zachariah, MD;
Lloyd D. Fisher, PhD;
Ralph E. Spiekerman, MD;
Fred J. Araas, MD;
John B. Collins, MD;
David C. Agerter, MD
Arch Intern Med. 1987;147(2):291-296.
Abstract
• Ketanserin, a serotonin receptor antagonist (S2), lowered blood pressure in patients with essential hypertension; at three months 72% (13/18) had a successful reduction in pressure. No marked orthostatic changes were noted. Older patients responded better when standing. Compared with metoprolol, ketanserin provided no significant difference in response at three months. With ketanserin, the heart rate was reduced only in the supine position, whereas it was reduced in the supine and standing positions with metoprolol. Response to ketanserin could not be predicted from baseline renin, aldosterone, or cortisol levels in blood, nor were there any changes in these factors or in plasma hydroxyindole levels with therapy. Ketanserin was generally well tolerated. Cholesterol values were significantly reduced with ketanserin, and there were no adverse hematologic or biochemical changes. Ketanserin should have a significant role in managing hypertension.
(Arch Intern Med 1987;147:291-296)
Author Affiliations
From the Departments of Internal Medicine (Drs Sheps, Schirger, Zachariah, and Spiekerman), Medical Statistics and Epidemiology (Dr Fisher), and Family Medicine (Drs Araas, Collins, and Agerter), Mayo Clinic and Mayo Foundation, Rochester, Minn.
Footnotes
Accepted for publication April 23, 1986.
Reprint requests to Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Sheps).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Effects of Antihypertensive Agents on Serum Lipids and Lipoproteins
Lardinois and Neuman
Arch Intern Med 1988;148:1280-1288.
ABSTRACT
|
